May 3, 2012

Metabolix Promotes Max Senechal to Vice President, Biobased Chemicals

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions for plastics, chemicals and energy, today announced the promotion of Max Senechal to vice president, biobased chemicals and his appointment to the executive management team. Mr. Senechal will be responsible for the commercialization of Metabolix's biobased industrial chemicals program, including the coordination of critical technical milestones and development of the customer base globally.

"We're pleased to recognize Max for his recent leadership of the Company's technical and commercial activities related to our biobased industrial chemicals platform," commented Richard P. Eno, president and CEO of Metabolix. "With recent advances in our chemicals business and growing market interest in our technology, Max will lead the team driving this platform ahead commercially and position Metabolix as a leader in the cost effective production of a wide range of biobased industrial chemicals."

Mr. Senechal brings to his new role more than 20 years of experience in the chemicals industry in both consulting and engineering. Mr. Senechal joined Metabolix in 2010 as director of strategy and commercial development, focused on the strategic direction and commercialization path for the Company's biobased industrial chemicals platform. From 2000 to 2010, Mr. Senechal served as a vice president for the chemicals, petroleum and life sciences practices at Charles River Associates International (CRA). At CRA, he focused on the development of business strategies, operations improvement projects and due-diligence engagements. From 1995 to 2000, Mr. Senechal was a senior manager at Arthur D. Little, where he was responsible for a wide range of consulting assignments for leading chemical companies across the globe. Prior to his consulting career, Mr. Senechal was a project engineer where he supervised the design, construction and start-up of industrial facilities in several industries including commodity, specialty, fine chemicals and pharmaceuticals. Mr. Senechal earned his MBA from the University of Massachusetts, Boston, and his B.S. in mechanical engineering from Laval University, Quebec, Canada.

About Metabolix

Metabolix, Inc. is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries. Metabolix is developing and commercializing MirelTM and Mvera,TM a family of high-performance bioplastics which are biobased and biodegradable alternatives to many petroleum-based plastics. Metabolix's biobased chemicals platform utilizes its novel "FAST" recovery process to enable the production of cost-effective, "drop-in" replacements for petroleum-based industrial chemicals. Metabolix is also developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.

For more information, please visit www.metabolix.com. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the ability to develop, commercialize and market biobased industrial chemicals, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2011, which was filed on March 12, 2012. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz MSL Boston
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzmsl.com
or
Investors:
ICR
James Palczynski, 203-682-8229
james.palczynski@icrinc.com

Source: Metabolix, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Yield10 Bioscience, Inc.